Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. filed a Current Report on Form 8-K on January 9, 2026 (Item 7.01) to disclose that it began using a new corporate presentation. A copy of the presentation is attached to the filing as Exhibit 99.1 (dated January 2026). The report was signed by President and CEO Shawn K. Singh.

Key Details

• Filing date: January 9, 2026 (Form 8-K, Item 7.01, Regulation FD Disclosure).
• Exhibit: 99.1 — Vistagen Therapeutics, Inc. Corporate Presentation, dated January 2026.
• Signed by: Shawn K. Singh, President and Chief Executive Officer.
• The report also includes the standard exhibits index and inline XBRL cover page file (Item 9.01).

Why It Matters
This filing publicly documents an updated investor-facing presentation and complies with Regulation FD (fair disclosure), ensuring the company’s corporate messaging is broadly available rather than shared selectively. For investors, the new presentation may contain updated strategy, program status, milestones, or guidance; review the attached Exhibit 99.1 for any specific operational or clinical updates. The 8-K does not report earnings, executive changes, or financial statements.